| CHAMBER OF COMMERCE OF THE U.S.A. | | 17 | $302.3M | Q3 2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | | 23 | $180.5M | Q3 2026 |
| AMERICAN HOSPITAL ASSOCIATION | | 23 | $132.1M | Q3 2026 |
| AMERICAN MEDICAL ASSOCIATION | | 23 | $125.0M | Q3 2026 |
| AARP | | 21 | $90.7M | Q1 2026 |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | | 23 | $78.0M | Q3 2026 |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | | 23 | $72.6M | Q3 2026 |
| PFIZER INC. | | 23 | $67.2M | Q3 2026 |
| AMGEN INC | | 23 | $64.3M | Q3 2026 |
| CVS HEALTH (AND SUBSIDIARIES) | | 23 | $59.8M | Q3 2026 |
| GENENTECH INC | | 23 | $55.4M | Q3 2026 |
| MERCK & CO INC | | 23 | $55.3M | Q3 2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | | 23 | $54.4M | Q3 2026 |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | | 23 | $53.1M | Q3 2026 |
| ELI LILLY AND COMPANY | | 23 | $49.8M | Q3 2026 |
| GILEAD SCIENCES INC | | 23 | $48.2M | Q3 2026 |
| UNITEDHEALTH GROUP INC | | 23 | $43.8M | Q3 2026 |
| BAYER CORPORATION (CONSOLIDATED REPORT) | | 23 | $42.6M | Q3 2026 |
| BRISTOL-MYERS SQUIBB COMPANY | | 23 | $42.6M | Q3 2026 |
| ELEVANCE HEALTH, INC. | | 23 | $39.8M | Q3 2026 |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | | 23 | $39.4M | Q3 2026 |
| NOVARTIS | | 23 | $37.9M | Q3 2026 |
| FRESENIUS MEDICAL CARE NORTH AMERICA | | 23 | $36.5M | Q3 2026 |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | | 23 | $33.9M | Q3 2026 |
| ABBVIE INC. | | 23 | $33.3M | Q3 2026 |
| AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION | AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION FKA PROPERTY CASUALTY INSURERS ASSOC. OF AMERICA | 22 | $32.7M | Q3 2026 |
| SANOFI US SERVICES INC | | 23 | $31.3M | Q3 2026 |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.) | NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES | 23 | $30.2M | Q3 2026 |
| AMERICAN ASSOCIATION FOR JUSTICE | | 23 | $29.9M | Q3 2026 |
| NOVO NORDISK INC. | | 23 | $29.2M | Q3 2026 |
| HUMANA INC | | 23 | $29.0M | Q3 2026 |
| GSK (FKA GLAXOSMITHKLINE INC.) | | 23 | $28.6M | Q3 2026 |
| KAISER FOUNDATION HEALTH PLAN INC | | 23 | $27.1M | Q3 2026 |
| CENTENE CORPORATION | | 23 | $26.6M | Q3 2026 |
| ASTRAZENECA PHARMACEUTICALS LP | | 23 | $25.8M | Q3 2026 |
| MEDTRONIC INC | | 23 | $25.3M | Q3 2026 |
| ABBOTT LABORATORIES | | 23 | $25.3M | Q3 2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | | 23 | $24.4M | Q3 2026 |
| HEALTH CARE SERVICE CORPORATION, A MUTUAL LEGAL RESERVE COMPANY (HCSC) | | 23 | $24.3M | Q3 2026 |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 23 | $23.6M | Q3 2026 |